Trials / Completed
CompletedNCT02575651
A Phase I Study of Fluzoparib in Patient With Advanced Solid Malignancies
A Phase I, Open-label, Dose Escalation Study to Assess the Safety and Tolerability of Fluzoparib Following Single and Multiple Oral Doses in Patients With Advanced Solid Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 79 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Fluzoparib is an oral potent, selective PARP-1 and PARP-2 inhibitor. The objective of this study will be to investigate the safety and tolerability of Fluzoparib Capsule when given orally to Chinese patients with advanced solid malignancies. In addition, the pharmacokinetic profile, MTD (if possible) and efficacy of Fluzoparib will be investigated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fluzoparib | Fluzoparib either at 10,20,40,80,120mg ....., capsule oral. |
Timeline
- Start date
- 2015-04-01
- Primary completion
- 2018-06-01
- Completion
- 2018-06-01
- First posted
- 2015-10-15
- Last updated
- 2019-06-17
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02575651. Inclusion in this directory is not an endorsement.